Spun out of MIT with the defined objective of improving overall human health by monitoring the disease as well as detecting the stage and growing rate of the same, Glympe Bio is building on the foundation of platform technology initially developed at MIT to detect early stage cancer, blood clotting diseases and fibrosis of the fatty liver. Currently resident in JLab Cambridge, Glympse is developing bioengineered in vivo sensors to detect disease and monitor drug response. The companyâs technology involves customizable injectable nanoparticles designed to interact with disease-associated enzymes and then to release a chemical signal that is excreted through the urine. Glympseâs initial focus had been on nonalcoholic steatohepatitis (NASH), with clinical trials undertaken during 2019. Additional potential indications include cancer, fibrosis, and infectious diseas
